Fagron Sa · EURONEXT:FAGR
Fagron Sa — Q1 2024 Earnings Presentation
9 slides from Fagron Sa's earnings presentation, Apr 11, 2024
Slide 1: Q1 2024 Results
Q1 2024 Results 11 April 2024 Rafael Padilla Karin de Jong CEO CFO
Slide 2: Disclaimer
Disclaimer The contents of this document, including all statements made therein, are based on estimates, assumptions and other information currently available to the management of Fagron. Certain statements in this presentation may be deemed to be forward-looking. Such forward-looking statements are
Slide 3: Record revenue of €209 million for the first quarter
Record revenue of €209 million for the first quarter Revenue growth of 15.3% supported by strong organic growth, M&A and FX Q1 2024 Organic growth supported by strong performance at FSS and Anazao in North America, and CS in EMEA Total revenue €209.2m Continued execution on strategic initiatives and
Slide 4: Revenue growth reflects contributions across the board
Revenue growth reflects contributions across the board Revenue bridge (€ m) 220.0 210.0 4.7 0.8 200.0 190.0 19.3 2.8 0.3 180.0 170.0 209.2 160.0 150.0 181.4 140.0 130.0 120.0 Q1 2023 EMEA Latin America North America Acquisitions FX Q1 2024 Commercial execution benefits Procurement savings and Well-p
Slide 5: Leveraging global leadership combined with operational efficiencies
Leveraging global leadership combined with operational efficiencies EMEA Latin America North America + 10.2% + 5.7% + 26.1% 100.0 60.0 100.0 88.3 90.0 79.6 41.4 90.0 50.0 80.0 72.2 39.1 80.0 70.0 1.1 70.0 70.0 60.0 20.3 26.6 40.0 0.7 60.0 50.0 30.0 11.8 13.9 50.0 65.9 40.0 12.8 12.3 40.0 48.0 20.0 3
Slide 6: Poland: Regulatory impact managed proactively by commercial agility
Poland: Regulatory impact managed proactively by commercial agility Background & subsequent developments Fagron: Clear strategic actions Law adopted containing changes to reimbursement system Provide expert input to for overall pharmaceutical market government working group Continued proactive and r
Slide 7: FY 2024 outlook
FY 2024 outlook 2024 Outlook Mid-term targets: 2022 - 2026 Organic revenue growth High single-digit +8% CAGR REBITDA margin Increase in profitability YoY Consistent with 2017-21 average Capex as % of revenue 3 – 3.5% of revenue* 3 – 3.5% of revenue* 12.5 – 13.5% of revenue at year-end 10 – 11% of re
Slide 8: Together
Global leader in the niche pharmaceutical compounding market Unique Market Positioning Defensive Business Model Strong Cash Generation Sustainability Focus Disciplined M&A Together we create the future of Operational Excellence personalized medicine 8
Slide 9: Questions
Questions ersonalizin fredicine Fag